Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$81.16
+0.9%
$72.80
$61.24
$87.68
$251.46B0.365.24 million shs766,558 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.29
+0.5%
$38.35
$31.72
$44.67
$82.03B0.515.14 million shs597,770 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$606.72
+1.4%
$549.27
$476.49
$1,211.20
$64.17B0.331.10 million shs227,898 shs
Sanofi stock logo
SNY
Sanofi
$51.49
+1.7%
$48.59
$44.73
$60.12
$126.18B0.482.55 million shs376,262 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
-0.07%+2.54%+14.16%+14.27%-5.96%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-0.03%+2.17%+8.22%+3.49%-4.31%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.21%+5.69%+6.64%+1.67%-49.54%
Sanofi stock logo
SNY
Sanofi
+0.16%+3.20%+3.82%-2.64%-8.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.6274 of 5 stars
1.45.02.50.04.00.01.3
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.893 of 5 stars
0.95.02.50.04.00.02.5
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.8326 of 5 stars
4.43.01.72.33.41.71.9
Sanofi stock logo
SNY
Sanofi
3.8549 of 5 stars
2.65.02.50.03.40.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.80
Moderate Buy$86.005.96% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.88
Reduce$37.38-7.24% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.81
Moderate Buy$829.6536.74% Upside
Sanofi stock logo
SNY
Sanofi
3.11
Buy$62.0020.42% Upside

Current Analyst Ratings Breakdown

Latest SNY, REGN, AZN, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/14/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$890.00
8/11/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$940.00 ➝ $812.00
8/8/2025
Sanofi stock logo
SNY
Sanofi
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight
8/5/2025
Sanofi stock logo
SNY
Sanofi
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/4/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$600.00 ➝ $640.00
8/4/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$688.00 ➝ $695.00
8/1/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$810.00 ➝ $815.00
8/1/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$580.00
8/1/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
8/1/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$754.00 ➝ $761.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.65$6.35 per share12.79$14.45 per share5.62
GSK PLC Sponsored ADR stock logo
GSK
GSK
$31.63B2.60$5.61 per share7.18$9.41 per share4.28
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.20B4.53$46.92 per share12.93$282.48 per share2.15
Sanofi stock logo
SNY
Sanofi
$44.46B2.84$5.43 per share9.48$32.49 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.6630.4816.231.4814.68%32.84%12.87%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$2.1618.648.661.7410.81%49.22%11.31%10/29/2025 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$39.6815.2615.961.9731.37%15.06%11.77%10/30/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$4.1612.3510.841.2121.47%16.86%9.63%10/24/2025 (Estimated)

Latest SNY, REGN, AZN, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q2 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.43$12.89+$4.46$12.81$3.30 billion$3,675,600.00 billion
7/31/2025Q2 2025
Sanofi stock logo
SNY
Sanofi
$0.96$0.90-$0.06$1.84$9.91 billion$11.34 billion
7/30/2025Q2 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion
7/29/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.09$1.09N/A$0.79$14.08 billion$14.46 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.011.24%N/A37.97%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.684.17%N/A77.78%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.520.58%N/A8.87%N/A
Sanofi stock logo
SNY
Sanofi
$1.603.11%N/A38.46%N/A

Latest SNY, REGN, AZN, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
7/29/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$0.50502%8/8/20258/8/20259/8/2025
8/18/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.6%8/18/20258/18/20259/3/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.55
0.86
0.67
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.07
0.87
0.57
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.60
3.72
Sanofi stock logo
SNY
Sanofi
0.19
1.27
0.94

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Sanofi stock logo
SNY
Sanofi
14.04%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7.02%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.04 billion1.83 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,106105.99 million98.55 millionOptionable
Sanofi stock logo
SNY
Sanofi
82,8782.46 billion2.43 billionOptionable

Recent News About These Companies

Sanofi $SNY Shares Sold by Wellington Management Group LLP
Sanofi $SNY Stock Holdings Lowered by Aberdeen Group plc
Sanofi $SNY Shares Purchased by Brooklyn Investment Group
Sanofi $SNY Shares Sold by American Century Companies Inc.
Sanofi (NASDAQ:SNY) Shares Bought by Ethic Inc.
Sanofi (NASDAQ:SNY) Receives Average Rating of "Buy" from Analysts

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$81.16 +0.70 (+0.87%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK stock logo

GSK NYSE:GSK

$40.29 +0.21 (+0.53%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$606.72 +8.56 (+1.43%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Sanofi stock logo

Sanofi NASDAQ:SNY

$51.49 +0.88 (+1.73%)
As of 10:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.